Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.
Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (Bekaii-Saab T, et al. ASCO 2024. Abstract 3579.)
Impact of prior bevacizumab
Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing: